Cargando…

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Red Cells and Iron
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594003/ https://www.ncbi.nlm.nih.gov/pubmed/30768680 http://dx.doi.org/10.1111/bjh.15790

Ejemplares similares

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
por: Peffault de Latour, Régis, et al.
Publicado: (2020)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017)

Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias
por: Vinchi, Francesca, et al.
Publicado: (2021)

Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
por: Adhikari, Sugat, et al.
Publicado: (2023)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
por: Walle, J Vande, et al.
Publicado: (2015)

Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012)

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)

Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria
por: Eliesen, Gaby A.M., et al.
Publicado: (2020)

Paroxysmal nocturnal haemoglobinuria and diabetes mellitus.
por: Andrews, W. J., et al.
Publicado: (1990)

Coombs-positive Paroxysmal Nocturnal Haemoglobinuria
por: Kalam, Sabrina, et al.
Publicado: (2020)

Eculizumab treatment for paroxysmal nocturnal haemoglobinuria in a patient with recurrent simultaneous multivessel coronary stent thrombosis
por: De Maria, Giovanni Luigi, et al.
Publicado: (2015)

Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014)

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)

Paroxysmal Nocturnal Haemoglobinuria: Clinical-Pathological Conference
por: Hewer, T. F.
Publicado: (1963)

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A
Publicado: (2022)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012)

Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab
por: Jeantet, Guillaume, et al.
Publicado: (2018)

Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials
por: Walle, J Vande, et al.
Publicado: (2015)

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
por: Cançado, Rodolfo D., et al.
Publicado: (2021)

Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A.
Publicado: (2023)

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises
por: Krishnan, Suba, et al.
Publicado: (2010)

Transfer of 4-hydroxynonenal from parasitized to non-parasitized erythrocytes in rosettes. Proposed role in severe malaria anemia
por: Uyoga, Sophie, et al.
Publicado: (2012)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Risk factors for high cerebral blood flow velocity and death in Kenyan children with Sickle Cell Anaemia: role of haemoglobin oxygen saturation and febrile illness
por: Makani, Julie, et al.
Publicado: (2009)

Haptoglobin, alpha‐thalassaemia and glucose‐6‐phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania
por: Cox, Sharon E., et al.
Publicado: (2014)

Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection
por: Cserti-Gazdewich, Christine M, et al.
Publicado: (2012)

Epistasis and the sensitivity of phenotypic screens for beta thalassaemia
por: Penman, Bridget S, et al.
Publicado: (2015)

Bacteraemia in sickle cell anaemia is associated with low haemoglobin: a report of 890 admissions to a tertiary hospital in Tanzania
por: Makani, Julie, et al.
Publicado: (2015)

The transcription factor ATOH8 is regulated by erythropoietic activity and regulates HAMP transcription and cellular pSMAD1,5,8 levels
por: Patel, Neeta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kdea4q701rpo6necinv35r43os